Performance and Safety of Otinova® Ear Spray

Inclusion Criteria: * Male or female ≥ 5 years old * Clinical diagnosis of otitis externa based on otoscopic exam: a.Defined as a clinical score of at least 1, on a scale from 0 to 2 (none, mild/moderate, severe), for at least one of the OE signs (swelling, erythema and otorrhea) * Ability to correctly administer Otinova as spray (not requiring tamponade), as judged by the Investigator * Subject agrees to refrain from water immersion of the ears during the investigation * Subject agrees to refrain from using other ear treatment products during the investigation * For pediatric patients, provision of informed consent by subject and legal -Subject, and if applicable legal representative(s), are willing to comply with the protocol and attend all investigation visits. Exclusion Criteria: * Duration of OE signs/symptoms longer than 6 weeks * Suspected perforated eardrum or eardrum fitted with drainage tube * Post-mastoid surgery * Prior otologic surgery within 6 months of enrollment (must be successfully healed) * Conditions which may make it difficult to evaluate the therapeutic response (e.g malignant OE, abscess, granulation, polyps, congenital disorders) * History of malignant tumors in the external ear canal, or currently receiving chemotherapy or radiation therapy * Known allergy or sensitivity to any component of the device * Use of topical or systemic antibiotics, corticosteroids or other treatment that could affect the study result within 7 days prior to enrolment * Pregnancy or lactation at time of enrolment * Subjects with any other condition that, as judged by the investigator, may make investigation procedures inappropriate * Participation in another clinical investigation within 30 days of screening